Magnitude of Precancerous Cervical Lesion and Associated Factors among HIV-Positive Women Attending Adult ART Clinic at Public Health Facilities In Arsi Zone, Oromia Region: Institutional Based Cross-Sectional Study
This 2025 institutional cross-sectional study in Arsi Zone, Ethiopia, found a 16.1% prevalence of precancerous cervical lesions among HIV-positive women, identifying factors such as shorter duration on antiretroviral therapy, history of sexually transmitted infections, early sexual debut, oral contraceptive use, abortion history, and family history of cervical cancer as significant predictors.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cervical cancer begins with small, abnormal changes in the cells of the cervix, the lower part of the uterus. These changes, known as precancerous lesions, do not appear suddenly; they develop slowly over time, often starting with an infection from a virus called human papillomavirus, or HPV. While the human body can sometimes clear this virus on its own, in some cases, the infection persists and gradually transforms healthy cells into dangerous ones. This process is particularly risky for women living with HIV, a virus that weakens the immune system. When the immune system is compromised, it struggles to fight off the HPV infection, allowing precancerous changes to take hold and progress more quickly than they would in someone with a healthy immune system. Because these early changes can be spotted and treated before they become cancer, finding them early is one of the most effective ways to prevent the disease from developing at all.
In a recent study conducted in the Arsi Zone of Ethiopia, researchers set out to understand how common these precancerous lesions are among women living with HIV who are receiving treatment at public health clinics. The team focused on 422 women who were attending adult antiretroviral therapy (ART) clinics, which provide medication to manage HIV. The study took place over a month in late 2025. To find the lesions, the medical team used a simple, visual screening method called visual inspection with acetic acid. In this procedure, a doctor applies a mild vinegar-like solution to the cervix. If precancerous cells are present, they turn a distinct white color, making them visible to the naked eye without the need for complex laboratory equipment. This approach is especially valuable in resource-limited settings because it allows for immediate detection and, if necessary, immediate treatment during the same visit.
The results of the screening revealed a significant public health concern. Out of the 422 women examined, 16.1 percent were found to have precancerous cervical lesions. This means that roughly one in every six women in this group had abnormal cell changes that could lead to cancer if left untreated. Among those with positive results, nearly all were eligible for a simple treatment called cryotherapy, which freezes the abnormal tissue to remove it, and they received this treatment immediately. A small number of women showed signs that were suspicious for invasive cancer, and they were referred to a hospital for further diagnosis and care. The study confirmed that while these women were receiving life-saving HIV medication, they remained highly vulnerable to cervical abnormalities, highlighting a critical gap in comprehensive care that needs to be addressed.
Beyond simply counting how many women had lesions, the researchers investigated what specific factors made some women more likely to develop these changes than others. They looked at a wide range of details, including the women's ages, their reproductive histories, their sexual behaviors, and how long they had been on HIV treatment. The analysis uncovered six key factors that were strongly linked to the presence of precancerous lesions. First, women who had used oral contraceptive pills at some point in their lives were much more likely to have lesions. Second, women who began having sexual intercourse at a young age, specifically before turning 18, faced a significantly higher risk. Third, a history of sexually transmitted infections was a major predictor, as was having a family history of cervical cancer. Fourth, women who had experienced an abortion were also found to be at greater risk. Finally, and perhaps most importantly for clinical management, the length of time a woman had been taking her HIV medication mattered greatly. Women who had been on treatment for less than one year were far more likely to have lesions than those who had been on treatment for four years or longer.
These findings suggest that the risk of developing precancerous lesions in women with HIV is shaped by a combination of biological, behavioral, and treatment-related factors. The strong link between shorter treatment duration and higher lesion rates points to the vital role of the immune system. It appears that as women stay on HIV medication for longer periods, their immune systems recover enough to better control the HPV virus and prevent it from causing cellular damage. Conversely, the connections to early sexual activity, past infections, and family history indicate that certain life experiences and genetic backgrounds create a foundation of risk that persists even while a woman is receiving medical care. The study does not claim to prove that these factors cause the lesions in every single case, but the statistical evidence is strong enough to suggest they are independent drivers of the problem.
The implications of this research are clear for the way healthcare is delivered to women living with HIV in this region. The high prevalence of lesions indicates that screening cannot be an afterthought; it must be a routine part of the care these women receive. The study suggests that clinics should not only screen all women on ART but also pay special attention to those with specific risk factors, such as a family history of cancer or those who have recently started their medication. By integrating cervical cancer screening directly into HIV treatment programs, health workers can catch these dangerous changes early, often before a woman even feels sick. This approach turns a potential tragedy into a manageable health issue, ensuring that the life-saving benefits of HIV treatment are not undermined by a preventable cancer. The work underscores that protecting the health of women with HIV requires looking beyond the virus itself to the full picture of their lives, their histories, and their immune recovery.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.